HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS IN PATIENTS WITH METASTATIC UROTHELIAL CANCER (MUC) WHO RECEIVED FIRST-LINE (1L) TREATMENT: RESULTS FROM IMPACT UC II

被引：0
|
作者：
Bilen, M. A. [1 ]
Diessner, B. [2 ]
White, J. [2 ]
Kirker, M. [3 ]
Liu, F. [4 ]
Nguyen, A. [2 ]
Gharibian, N. [3 ]
Devgan, G. [3 ]
Katzenstein, H. [4 ]
Bhanegaonkar, A. [4 ]
机构：
[1] Winship Canc Inst Emory Univ, Atlanta, GA USA
[2] Optum, Eden Prairie, MN USA
[3] Pfizer, New York, NY USA
[4] EMD Serono, Rockland, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE390
引用
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [41] First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA
    Broder, Michael S.
    Cai, Beilei
    Chang, Eunice
    Yan, Tingjian
    Benson, Al B., III
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 821 - 826
  • [42] PREDICTING TREATMENT EFFECTS FROM SURROGATE ENDPOINTS IN FIRST-LINE (1L) METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Samjoo, I
    Disher, T.
    Castro, E.
    Ellis, J.
    Paganelli, S.
    Nazari, J.
    Niyazov, A.
    VALUE IN HEALTH, 2023, 26 (12) : S25 - S25
  • [43] Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Sotelo, Miguel
    Chara, Luis
    Riquelme, Alejandro
    Toro, Piedad
    Lopez, Cynthia
    Hernando, Susana
    Caviedes, Edinson
    Aguayo, Cristina
    Bueno, Coralia
    Mielgo Rubio, Xabier
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1340 - S1341
  • [44] First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC)
    Rosenberg, J. E.
    Flaig, T. W.
    Friedlander, T. W.
    Milowsky, M. I.
    Srinivas, S.
    Petrylak, D. P.
    Merchan, J. R.
    Bilen, M. A.
    Carret, A. -S.
    Yuan, N.
    Sasse, C.
    Hoimes, C. J.
    SWISS MEDICAL WEEKLY, 2020, : 26S - 27S
  • [45] Phase II trial of palbociclib (PD-0332991) in patients with metastatic urothelial cancer (UC) after failure of first-line chemotherapy.
    Rose, Tracy Lynn
    Chism, David D.
    Alva, Ajjai Shivaram
    Deal, Allison Mary
    Maygarden, Susan
    Whang, Young E.
    Kardos, Jordan
    Drier, Anthony
    Kim, William Y.
    Milowsky, Matthew I.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [46] Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC).
    Bloudek, Lisa
    Hepp, Zsolt
    Mckay, Caroline
    Derleth, Christina Louise
    Lill, Jennifer Susan
    Lenero, Enrique
    Wright, Phoebe
    Ramsey, Scott David
    Sullivan, Sean D.
    Devine, Beth
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [47] Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC)
    Bloudek, Lisa
    Wright, Phoebe
    McKay, Caroline
    Derleth, Christina Louise
    Lill, Jennifer Susan
    Lenero, Enrique
    Hepp, Zsolt
    Ramsey, Scott David
    Sullivan, Sean D.
    Devine, Beth
    CURRENT ONCOLOGY, 2023, 30 (04) : 3637 - 3647
  • [48] Systematic literature review (SLR) and network meta-analysis (NMA) of first-line (1L) therapies for locally advanced/metastatic urothelial carcinoma (la/mUC)
    Bloudek, L.
    Hepp, Z.
    Mckay, C.
    Devine, B.
    Derleth, C.
    Lill, J.
    Lenero, E.
    Wright, P.
    Ramsey, S. D.
    Sullivan, S. D.
    ANNALS OF ONCOLOGY, 2021, 32 : S715 - S715
  • [49] First-line chemotherapy for HER-2-negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment
    Morabito, Alessandro
    Piccirillo, Maria Carmela
    Monaco, Katia
    Pacilio, Carmen
    Nuzzo, Francesco
    Chiodini, Paolo
    Gallo, Ciro
    De Matteis, Andrea
    Perrone, Francesco
    ONCOLOGIST, 2007, 12 (11): : 1288 - 1298
  • [50] First-line (1L) treatment (tx) patterns and criteria used to determine platinum eligibility (PE) in platinum-eligible and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in South Korea (KR) and Taiwan (TW)
    Milloy, N.
    Berry, M.
    Montgomery, R.
    Kluth, C.
    Bleasdale, C.
    Kirker, M.
    Kearney, M.
    Mohamed, W. E. M.
    Costa, N.
    Chang, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1490 - S1490
12345